AK112 with chemo or olaparib for platinum-sensitive ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called AK112 combined with chemotherapy or another drug (olaparib) for people with ovarian cancer that came back more than 6 months after platinum treatment. The goal is to see if these combinations work better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with platinum-sensitive ovarian cancer (came back more than 6 months after platinum chemo).
- Your cancer must be measurable on scans and you must have a tumor sample available for testing.
- You must be in good enough health to walk and care for yourself (ECOG 0 or 1).
- If you have a BRCA gene mutation, you must have already tried a PARP inhibitor like olaparib.
- You cannot have had certain prior treatments like immunotherapy or live vaccines, or have other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
This trial tests a new drug called AK104, which helps the immune system fight cancer, combined with chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this combination can shrink tumors enough to make surgery more successful.
This trial tests a new drug called AK112 combined with chemotherapy as a first treatment for people with metastatic colorectal cancer. The goal is to see if the combination helps shrink tumors and improve survival better than chemotherapy alone.
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
Hear when a new Platinum-sensitive Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.